Avacta Group Plc (FRA:RTQ1)

Market Cap	406.77M
Revenue (ttm)	131.83K
Net Income (ttm)	-73.03M
Shares Out	n/a
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,000
Average Volume	n/a
Open	0.8600
Previous Close	0.8700
Day's Range	0.8600 - 0.8600
52-Week Range	0.2920 - 0.9050
Beta	n/a
RSI	61.79
Earnings Date	Apr 23, 2026

About Avacta Group

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv...

• Industry: Commercial Physical and Biological Research
• Founded: 2003
• Employees: 151
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RTQ1

Financial Performance

In 2024, Avacta Group's revenue was 113,000, a decrease of -96.04% compared to the previous year's 2.85 million. Losses were -52.84 million, 58.9% more than in 2023.

Financial numbers in GBP